Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA) Dec 2, 2009 04:08PM

Cephalon, Inc. (Nasdaq: CEPH) filed a lawsuit in U.S. District Court in Delaware against Teva Pharmaceuticals USA, Inc. (Nasdaq: TEVA) for infringement of U.S. Patent Nos. 7,132,570, 7,297,346 and RE37,516 for the Cephalon product NUVIGIL Tablets.

The lawsuit is based upon an Abbreviated New Drug Application (ANDA) filed by Teva seeking FDA approval for a generic equivalent of armodafinil to be sold in the United States. Teva alleges that the above NUVIGIL patents are invalid, unenforceable and/or will not be infringed by Teva's manufacture, use or sale of the product described in its ANDA.

"We believe that our NUVIGIL patents, approved by the US Patent & Trademark Office, are valid, enforceable and are infringed by the proposed Teva ANDA product ," said Jerry Pappert, Executive Vice President and General Counsel. "


Needham Lifts Price Target on Dyax (DYAX) to $8 Dec 2, 2009 09:56AM

Needham & Co lifted theier price targete on Dyax Corp. (Nasdaq: DYAX) to $8 from $6, following FDA approval of KALBITOR for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older. The firm's Buy rating was maintained.

Analyst Mark Monane states "We are encouraged by KALBITOR label for treatment in HAE regardless of anatomic location and note that KALBITOR represents the only approved treatment option for life-threatening laryngeal attacks. The Company is working on a pediatric development plan for KALBITOR with the EMEA, and while the US KALBITOR label did not include an indication in patients 12-15 years old, we expect off-label use in this population due to multiple similarities with adults, yet limited use in patients 9-12 years old. As we expected, KALBITOR use, although given SQ, is limited at this time to the ER or medical office area: future studies are planned to optimize use of KALBITOR in further outpatient or home settings."


Novo Nordisk (NVO) Atophic Vaginitis Treatment Approved by U.S. FDA Dec 2, 2009 09:18AM

Novo Nordisk (NYSE: NVO) said today that the U.S. Food and Drug Administration (FDA) has approved a 10 mcg dose formulation of Vagifem (estradiol vaginal tablets) for the treatment of atrophic vaginitis due to menopause - a condition experienced by up to 75 percent of postmenopausal women. This approval makes Vagifem 10 mcg the lowest local estrogen therapy (LET) dose commercially available in the U.S. It will be available in pharmacies in the first quarter of 2010.

Atrophic vaginitis, commonly referred to as vaginal atrophy, is directly related to the loss of estrogen associated with menopause. It is caused by the resulting thinning and shrinking of vaginal tissues and the decreased lubrication of the vaginal walls, which can lead to vaginal dryness, soreness, vaginal and or vulvar itching and irritation, painful sexual intercourse and light bleeding after intercourse.


AEterna (AEZS) Announces FDA Fast Track Status for KRX-0401 Dec 2, 2009 08:39AM

AEterna Zentaris Inc. (NASDAQ: AEZS) announced that the FDA has granted Fast Track designation for the Company's PI3K/Akt pathway inhibitor compound, perifosine (KRX-0401), for the treatment of relapsed/refractory multiple myeloma.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KER), is AEterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs ordinarily qualify for priority review, thereby expediting the FDA review process.


Keryx (KERX) Granted FDA Fast Track Designation for KRX-0401 Dec 2, 2009 08:34AM

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) said the FDA has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.


More FDA

View Older Stories

Dec 1, 2009 05:56PM Dyax (DYAX) Receives FDA Approval of KALBITOR(R) for Treatment of Acute Attacks of Hereditary Angioedema
Dec 1, 2009 05:23PM Santarus (SNTS) Earns $20 Million Milestone on FDA Approval for NDA of ZEGERID
Dec 1, 2009 05:06PM Santarus (SNTS) Jumps Ahead of Expected News
Dec 1, 2009 04:35PM Hemispherx Biopharma (HEB) Receives Letter for Ampligen From US FDA; FDA Cannot Approve Application in Present Form
Dec 1, 2009 04:34PM Hemispherx (HEB) Falls 30% as FDA Recommends Another Ampligen Study, Says Can't Approve Application in Present Form
Dec 1, 2009 03:45PM Positives Seen On BioCryst (BCRX) After Peramivir Granted Priority Review In Japan
Dec 1, 2009 10:00AM Teva Pharma (TEVA) Submits BLA to U.S. FDA for XM02
Dec 1, 2009 09:11AM Protalix (PLX) Sells-Off On Pfizer News, As Fast Money Disappointed In No Takeover
Dec 1, 2009 07:16AM Masimo (MASI) Receives FDA Clearance for Rainbow SET Acoustic Monitoring
Dec 1, 2009 06:41AM Protalix (PLX) Enters Deal With Pfizer (PFE) To Develop Gaucher's Disease Treatment
Nov 30, 2009 05:29PM Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
Nov 30, 2009 04:04PM Human Genome Sciences (HGSI) To Offer Up to 12.5M Shares
Nov 30, 2009 02:32PM ZymoGenetics (ZGEN) Higher Ahead of Presentation
Nov 30, 2009 11:24AM Somaxon Pharmaceuticals (SOMX) Surges Ahead of FDA Action Date
Nov 30, 2009 09:04AM BioMarin Pharmaceutical (BMRN) Announces FDA Grants Orphan Drug Designation for 3,4-DAP
Nov 30, 2009 08:03AM FDA Approves Cymbalta (LLY) for Treatment of Generalized Anxiety Disorder
Nov 30, 2009 07:31AM Eurand N.V. (EURX) Announces Availability of ZENPEP
Nov 30, 2009 07:08AM Spectrum Pharma (SPPI) Phase 3 Apaziquone Enrollment Complete
Nov 25, 2009 09:26AM RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
Nov 25, 2009 09:20AM Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
Nov 25, 2009 07:18AM Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
Nov 25, 2009 06:36AM Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
Nov 24, 2009 04:18PM Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
Nov 24, 2009 08:47AM Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
Nov 23, 2009 04:27PM Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
Nov 23, 2009 03:44PM DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
Nov 23, 2009 10:53AM Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
Nov 23, 2009 08:49AM ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
Nov 23, 2009 08:06AM Ception and Cephalon (CEPH) Report Initial Results from Phase IIb/III Trial for CINQUIL(TM)
Nov 20, 2009 03:42PM Cornerstone Therapeutics (CRTX) Receives Warning Letter From FDA
Nov 20, 2009 01:22PM Pfizer (PFE) Gets Okay for Bipolar Treatment Geodon from U.S. FDA
Nov 20, 2009 01:21PM Intuitive Surgical (ISRG) Receives Japanese Approval for da Vinci
Nov 20, 2009 08:36AM Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
Nov 20, 2009 08:33AM Boston Scientific (BSX) Receives 510(k) Clearance and CE Mark on WallFlex
Nov 20, 2009 07:32AM Covidien (COV) Announces FDA Extends Review of NDA for Exalgo
Nov 19, 2009 04:40PM Matrixx Initiatives (MTXX) Files Response with FDA on Zicam
Nov 19, 2009 11:17AM Salix (SLXP) December volatility at 56, January at 68, April at 73 into PDUFA
Nov 18, 2009 11:36AM UnitedHealth's (UNH) Prescription Solutions Releases Study Finding No Significant Differences Between Ezetimibe/Simvastatin and Statin Alone
Nov 18, 2009 11:06AM BSD Medical (BSDM) Provides Update on FDA's Review of Company's BSD-2000 Hyperthermia System
Nov 18, 2009 09:01AM Medtronic (MDT) Receives FDA Warning Letter Following Inspection of Its Minnesota Facility
Nov 17, 2009 04:55PM VIVUS (VVUS) Will Announces Phase 3 Results of Avanafil Before The Market Opens
Nov 17, 2009 08:59AM NeurogesX (NGSX) Higher On FDA Approval of Qutenza
Nov 17, 2009 08:45AM Merck (MRK) Announces Results of COZAAR Study; Increased Dose Reduced Death or Hospitalization from Heart Failure
Nov 17, 2009 08:45AM InterMune (ITMN) Modifies On-Going Phase 2b Study of ITMN-191
Nov 17, 2009 07:31AM Discovery Laboratories (DSCO) Submits Propsed Protocol for Surfaxin Clinical to U.S. FDA
Nov 16, 2009 02:49PM Kinetic Concepts (KCI) Losses Bid To Halt Sales of Smith & Nephew Wound Kits - Bloomberg
Nov 16, 2009 02:21PM Cerus (CERS) Halted As FDA To Review Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
Nov 16, 2009 11:37AM ODAC to Review Using OSI Pharma's (OSIP) Tarceva as First-Line Therapy for Patients with Advanced Non-Small Cell Lung Cancer
Nov 16, 2009 09:28AM NovaDel Pharma (NVD) to Enter into Exclusive License and Distribution Agreement with ECR Pharma for ZolpiMist
Nov 16, 2009 09:19AM Genzyme (GENZ) Receives FDA Complete Response Letter Regarding Application to Market Lumizyme
View Older Stories